The new WHO guidance strengthens the fight against Plasmodium vivax malaria by combining safer radical cure medicines with routine G6PD testing to prevent dangerous side effects. By clearing both ...

On 18 December 2024, the World Health Organization (WHO) prequalified the first diagnostic test for glucose-6-phosphate dehydrogenase (G6PD) deficiency which can help to safely deliver WHO-recommended ...

DURHAM, N.C., Nov. 9, 2022 /PRNewswire/ -- Baebies has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its rapid, point-of-care test for glucose-6-phosphate dehydrogenase (G6PD) ...

The practice patterns and outlook of gynecology oncologists in the treatment of pediatric, adolescent and young adults with gynecologic malignancies: A survey study. This is an ASCO Meeting Abstract ...

MedTest Dx, Inc., an established solution provider for clinical diagnostic testing, is providing a critical tool in the fight against COVID-19 with its Pointe Scientific-branded assay for the highly ...

PATH and United Kingdom-based test developer Mologic have entered an agreement to advance a new rapid diagnostic test to support treatment and elimination of Plasmodium vivax, or relapsing, malaria.

We conducted a survey of malaria diagnoses and glucose-6-phosphate dehydrogenase (G6PD) testing in remote areas of Cambodia. Blood specimens from 670 people were collected by the finger-prick method.

To test tubes, 16 by 100 mm., are added 10 mg. of sodium ascorbate § and 5 mg. of glucose. These tubes are stoppered and may be stored indefinitely at -20°C. A 2.0-ml. aliquot of whole blood ...

Baebies has received US Food and Drug Administration (FDA) 510(k) clearance for its rapid, point-of-care test for glucose-6-phosphate dehydrogenase (G6PD) deficiency. The test is run on the FINDER ...